TABLE 2.
Characteristics and outcomes in DILI patients and non-DILI patients.
| Severity of DILI | Hep | Mix | Chol | |||
|---|---|---|---|---|---|---|
| Initial valuation (n = 10) | Revaluation (n = 2) | Initial valuation (n = 4) | Revaluation (n = 2) | Initial valuation (n = 41) | Revaluation (n = 21) | |
| Stage 1 | 5 (50.0%) | 1 (50.0%) | 2 (50.0%) | 1 (50.0%) | 25 (61.0%) | 11 (52.4%) |
| Stage 2 | 5 (50.0%) | 1 (50.0%) | 1 (25.0%) | 1 (50.0%) | 10 (24.4%) | 2 (9.5%) |
| Stage 3 | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) | 0 (0.0%) | 5 (12.2%) | 5 (23.8%) |
| Stage 4 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (2.4%) | 3 (14.3%) |
DILI, drug-induced liver injury; Hep, hepatocellular injury pattern; Mix, mixed injury pattern; Chol, cholestatic injury pattern.